<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511261</url>
  </required_header>
  <id_info>
    <org_study_id>HKESSNDCG/OMR/2014/CT1</org_study_id>
    <nct_id>NCT03511261</nct_id>
  </id_info>
  <brief_title>Efficacy of Curcumin in Oral Submucous Fibrosis</brief_title>
  <acronym>ECOSMF</acronym>
  <official_title>Innovative Formulations of Curcumin &amp; Its Comparative Efficacy in Management of Oral Submucous Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H.K.E.S's S.Nijalingappa Institute of Dental Science and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H.K.E.S's S.Nijalingappa Institute of Dental Science and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the formulations of curcumin will effect the
      clinical signs and symptoms and histopathological features in patients with clinical stage 2
      oral submucous fibrosis (OSMF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 clinical stage 2 OSMF patients selected randomly by simple random technique with
      clinically &amp; histopathologically confirmed diagnosis are divided into 4 groups with 50
      patients each.

      In Group 1 patients are given 10% of curcumin mucoadhesive gel and are instructed to use it
      topically twice daily making it a daily dose of 1gm.

      In Group 2 patients are given 500mg of curcumin capsules and are instructed to take 2
      capsules twice daily making a daily dose of 1gm.

      In Group 3 patients will be given 5% of curcumin mucoadhesive gel and will be instructed to
      use it topically twice daily &amp; 250mg of curcumin capsules to be taken twice daily making it a
      daily dose of 1gm.

      Group 4 is considered as control group and provided with formulations without the active
      drug.

      The mean scores of 4 groups will be statistically tested using Anova technique.

      The differences in clinical parameters at 15 days, 1 month, 3 months &amp; clinical &amp;
      histopathological paramerters at 6 months will be compared between groups 1, 2, 3 &amp; 4 by
      using students 't' test &amp; correlation is also used for knowing the association of variables.

      For all tests, a 'p' value of 0.05 or less will be utilized for statistical significance.

      Other non parametric tests can also be applied where ever necessary for data analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>four groups, each group with different formulations.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Burning sensation and pain</measure>
    <time_frame>6 months for each patient</time_frame>
    <description>Visual Analogue Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interincisal distance, tongue protrusion and cheek flexibility</measure>
    <time_frame>6 months for each patient</time_frame>
    <description>All these will be measured in mm at designated time intervals using digital vernier calliper.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Oral Submucous Fibrosis</condition>
  <arm_group>
    <arm_group_label>10%Curcumin mucoadhesive gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Curcumin arm Curcumin10% mucoadhesive gel
Group 1 patients:
Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin capsules 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 patients:
Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% Curcumin gel+Curcumin capsules 250mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 patients:
Drug: 5% Curcumin mucoadhesive gel &amp; Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% Curcumin mucoadhesive gel</intervention_name>
    <description>Group 1 10%of mucoadhesive gel for topical application two times per day.</description>
    <arm_group_label>10%Curcumin mucoadhesive gel</arm_group_label>
    <other_name>curcuminoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin capsules 500mg</intervention_name>
    <description>Group 2 curcumin 500 mg capsules for oral intake two times per day</description>
    <arm_group_label>Curcumin capsules 500mg</arm_group_label>
    <other_name>curcuminoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% curcumin mucoadhesive gel + Curcumin capsules 250 mg</intervention_name>
    <description>Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day</description>
    <arm_group_label>5% Curcumin gel+Curcumin capsules 250mg</arm_group_label>
    <other_name>curcuminoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Group 4 placebo capsules for oral intake two times per day</description>
    <arm_group_label>Placebo capsules</arm_group_label>
    <other_name>non curcuminoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  200 clinical stage 2 OSMF patients

        Exclusion Criteria:

          -  Clinical stage 1 &amp; 3 OSMF patients, oromucosal disorders with clinical features same
             as OSMF, patients who are under treatment, clinically diagnosed cases not ready for
             incisional biopsy, patients suffering from medically compromised conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syeda Arshiya Ara, MDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HKE'S S.N Institute of dental sciences &amp; research center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jayashree Mudda, MDS</last_name>
    <phone>+919741804012</phone>
    <email>jayashreemudda@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HKE'S S.N Institute of dental sciences &amp; research center</name>
      <address>
        <city>Gulbarga</city>
        <state>Karnataka</state>
        <zip>585102</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayashree Mudda, MDS</last_name>
      <phone>+919741804012</phone>
      <email>jayashreemudda@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Hazarey VK, Sakrikar AR, Ganvir SM. Efficacy of curcumin in the treatment for oral submucous fibrosis - A randomized clinical trial. J Oral Maxillofac Pathol. 2015 May-Aug;19(2):145-52. doi: 10.4103/0973-029X.164524.</citation>
    <PMID>26604488</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>H.K.E.S's S.Nijalingappa Institute of Dental Science and Research</investigator_affiliation>
    <investigator_full_name>Syeda Arshiya Ara</investigator_full_name>
    <investigator_title>Professor &amp; Research scholar</investigator_title>
  </responsible_party>
  <keyword>Oral submucous fibrosis</keyword>
  <keyword>curcumin</keyword>
  <keyword>potentially malignant disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Oral Submucous Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

